These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

363 related articles for article (PubMed ID: 33908208)

  • 1. Roles of Type I and III Interferons in COVID-19.
    Choi H; Shin EC
    Yonsei Med J; 2021 May; 62(5):381-390. PubMed ID: 33908208
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antiviral Activity of Type I, II, and III Interferons Counterbalances ACE2 Inducibility and Restricts SARS-CoV-2.
    Busnadiego I; Fernbach S; Pohl MO; Karakus U; Huber M; Trkola A; Stertz S; Hale BG
    mBio; 2020 Sep; 11(5):. PubMed ID: 32913009
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Type I and Type III Interferons - Induction, Signaling, Evasion, and Application to Combat COVID-19.
    Park A; Iwasaki A
    Cell Host Microbe; 2020 Jun; 27(6):870-878. PubMed ID: 32464097
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Type I IFNs: A Blessing in Disguise or Partner in Crime in MERS-CoV-, SARS-CoV-, and SARS-CoV-2-Induced Pathology and Potential Use of Type I IFNs in Synergism with IFN-
    Anjum FR; Anam S; Abbas G; Mahmood MS; Rahman SU; Goraya MU; Abdullah RM; Luqman M; Ali A; Akram MK; Chaudhry TH
    Viral Immunol; 2021 Jun; 34(5):321-329. PubMed ID: 33181057
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Type I and Type III Interferons Restrict SARS-CoV-2 Infection of Human Airway Epithelial Cultures.
    Vanderheiden A; Ralfs P; Chirkova T; Upadhyay AA; Zimmerman MG; Bedoya S; Aoued H; Tharp GM; Pellegrini KL; Manfredi C; Sorscher E; Mainou B; Lobby JL; Kohlmeier JE; Lowen AC; Shi PY; Menachery VD; Anderson LJ; Grakoui A; Bosinger SE; Suthar MS
    J Virol; 2020 Sep; 94(19):. PubMed ID: 32699094
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interplay between SARS-CoV-2 and the type I interferon response.
    Sa Ribero M; Jouvenet N; Dreux M; Nisole S
    PLoS Pathog; 2020 Jul; 16(7):e1008737. PubMed ID: 32726355
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Type I and III interferon responses in SARS-CoV-2 infection.
    Kim YM; Shin EC
    Exp Mol Med; 2021 May; 53(5):750-760. PubMed ID: 33953323
    [TBL] [Abstract][Full Text] [Related]  

  • 8. SARS-CoV-2 Is Restricted by Zinc Finger Antiviral Protein despite Preadaptation to the Low-CpG Environment in Humans.
    Nchioua R; Kmiec D; Müller JA; Conzelmann C; Groß R; Swanson CM; Neil SJD; Stenger S; Sauter D; Münch J; Sparrer KMJ; Kirchhoff F
    mBio; 2020 Oct; 11(5):. PubMed ID: 33067384
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Middle East Respiratory Syndrome Coronavirus Nucleocapsid Protein Suppresses Type I and Type III Interferon Induction by Targeting RIG-I Signaling.
    Chang CY; Liu HM; Chang MF; Chang SC
    J Virol; 2020 Jun; 94(13):. PubMed ID: 32295922
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dysregulated Interferon Response and Immune Hyperactivation in Severe COVID-19: Targeting STATs as a Novel Therapeutic Strategy.
    Eskandarian Boroujeni M; Sekrecka A; Antonczyk A; Hassani S; Sekrecki M; Nowicka H; Lopacinska N; Olya A; Kluzek K; Wesoly J; Bluyssen HAR
    Front Immunol; 2022; 13():888897. PubMed ID: 35663932
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition of SARS-CoV-2 by type I and type III interferons.
    Felgenhauer U; Schoen A; Gad HH; Hartmann R; Schaubmar AR; Failing K; Drosten C; Weber F
    J Biol Chem; 2020 Oct; 295(41):13958-13964. PubMed ID: 32587093
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Interferon induction, evasion, and paradoxical roles during SARS-CoV-2 infection.
    Chiale C; Greene TT; Zuniga EI
    Immunol Rev; 2022 Aug; 309(1):12-24. PubMed ID: 35775361
    [TBL] [Abstract][Full Text] [Related]  

  • 13. SARS-CoV-2 Evasion of the Interferon System: Can We Restore Its Effectiveness?
    Sacchi A; Giannessi F; Sabatini A; Percario ZA; Affabris E
    Int J Mol Sci; 2023 May; 24(11):. PubMed ID: 37298304
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mechanisms of Antiviral Immune Evasion of SARS-CoV-2.
    Beyer DK; Forero A
    J Mol Biol; 2022 Mar; 434(6):167265. PubMed ID: 34562466
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interferon therapy in patients with SARS, MERS, and COVID-19: A systematic review and meta-analysis of clinical studies.
    Saleki K; Yaribash S; Banazadeh M; Hajihosseinlou E; Gouravani M; Saghazadeh A; Rezaei N
    Eur J Pharmacol; 2021 Sep; 906():174248. PubMed ID: 34126092
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Broad-Spectrum Host-Based Antivirals Targeting the Interferon and Lipogenesis Pathways as Potential Treatment Options for the Pandemic Coronavirus Disease 2019 (COVID-19).
    Yuan S; Chan CC; Chik KK; Tsang JO; Liang R; Cao J; Tang K; Cai JP; Ye ZW; Yin F; To KK; Chu H; Jin DY; Hung IF; Yuen KY; Chan JF
    Viruses; 2020 Jun; 12(6):. PubMed ID: 32532085
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition of the IFN-α JAK/STAT Pathway by MERS-CoV and SARS-CoV-1 Proteins in Human Epithelial Cells.
    Zhang Y; Gargan S; Roche FM; Frieman M; Stevenson NJ
    Viruses; 2022 Mar; 14(4):. PubMed ID: 35458397
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Increased Sensitivity of SARS-CoV-2 to Type III Interferon in Human Intestinal Epithelial Cells.
    Metz-Zumaran C; Kee C; Doldan P; Guo C; Stanifer ML; Boulant S
    J Virol; 2022 Apr; 96(7):e0170521. PubMed ID: 35262371
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Characterization of SARS-CoV-2 Evasion: Interferon Pathway and Therapeutic Options.
    Znaidia M; Demeret C; van der Werf S; Komarova AV
    Viruses; 2022 Jun; 14(6):. PubMed ID: 35746718
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reconsideration of interferon treatment for viral diseases: Lessons from SARS, MERS, and COVID-19.
    Ma D; Wang X; Li M; Hu C; Tang L
    Int Immunopharmacol; 2023 Aug; 121():110485. PubMed ID: 37348227
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.